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Supervised Injecting Facilities – Annotated Bibliography 
The Drug Policy Modelling Program has prepared this annotated bibliography of published research concerned with Supervised Injecting Facilities, as at April 2012. We 
hope it will provide a useful resource for policy makers, clinicians and researchers interested in gaining an overview of the literature on this topic. 
An accompanying bulletin (http://www.dpmp.unsw.edu.au/DPMPWeb.nsf/resources/Bulletin5/$file/DPMP+Bulletin+22.pdf) provides a summary of the literature. 
The bibliography is structured into six main sections 
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Table 1: Reviews of the literature (n=8 papers)  
Reference Outcomes Examined Study period & 
location 
Aim/Description and findings  Unresolved Issues/ Notable Limitations 
Hedrich, D., Kerr, T., & Dubois-Arber, F. 
(2010). Drug consumption facilities in 
Europe and beyond. Lisbon: EMCDDA. 
 
See also: 
 
 Hedrich, D. (2004). European report on 
drug consumption rooms. Lisbon: 
EMCDDA 
 
Hunt, N. (2006b). The evaluation 
literature on drug consumption rooms. 
York: Joseph Rowntree Foundation.  
* An environment for safer drug 
use 
* Health status of target group 
* Public disorder 
Research up to 2010 
 
Worldwide 
Provides a comprehensive narrative review of the literature on SIFs, including 
non-English literature. Despite some limitations of the available evidence, the 
broad conclusion is that SIFs do bring benefits on specific aspects of individual 
and public health and social order without incurring serious risks. There is 
consistent evidence that SIFs are associated with reductions in injecting risk 
behaviour such as syringe sharing and public drug use, and increases in uptake 
of detoxification and treatment services. SIFs do not appear to increase levels of 
drug use or risky patterns of consumption, nor do they result in higher rates of 
local drug acquisition crime.  The evidence regarding effectiveness in reducing 
drug related deaths, HIV or hepatitis C virus (HCV) incidence is insufficient for 
drawing conclusions. To maximise the positive impacts of SIFs, adequate 
coverage is essential, as is political support and consensus between key actors 
Definitive conclusions are difficult to draw 
due to the difficulty proving causality 
through observational studies; ethical 
concerns prevent the 'gold standard' of 
randomly controlled trials from being 
conducted. Supersedes Hedrich (2004), 
which is often referred to as the most 
comprehensive and early review of SIFs. 
Hunt (2006) also described data from 
Hedrich (2004). 
Milloy, M. J., & Wood, E. (2009). 
Emerging role of supervised injecting 
facilities in Human Immunodeficiency 
Virus prevention. Addiction, 104(4), 620-
621. 
* Syringe lending and borrowing Various 
 
Spain & Vancouver 
Constructed a random-effects meta-analysis model to produce a pooled 
estimate of the relationship between SIF use and syringe sharing. Used three 
peer-reviewed studies (Bravo et al. 2009; Kerr, Tyndall, Li, Montaner &  Wood 
2005; Wood et al. 2005). 
The authors report a significant pooled effect size of 0.31 (95% CI 0.17–0.55) 
representing a 69% reduction in the likelihood of syringe sharing among SIF 
users 
Only used results from three different 
studies so may not be definitive 
Kerr, T., Kimber, J., DeBeck, K., & Wood, 
E. (2007). The role of safer injection 
facilities in the response to HIV/AIDS 
among injection drug users. Current 
HIV/AIDS Reports, 4(4), 158-164. 
* Reaching IDUs at high risk for 
HIV infection 
* Providing safer injecting 
education and addressing high-
risk injecting practices 
* Reducing syringe sharing 
* Promoting cessation of injecting 
* Reducing morbidity 
* Reducing mortality 
Research up to 2007 
 
Worldwide 
This narrative review considers the role of SIFs in stemming the harms 
specifically associated with HIV/AIDS in IDUs. The authors find that there is 
evidence that SIFs can complement the existing set of services. By attracting 
high-risk IDUs, providing safer injecting education, reducing syringe sharing, and 
promoting enrolment into drug treatment programs, SIFs can help prevent HIV 
transmission and promote greater stability among active IDUs. As well, by 
providing an alternative space for injection, SIFs can reduce unsafe injection 
practices associated with public injecting that increase risk for bacterial 
infections and other forms of morbidity common among IDUs who are HIV 
positive. Finally, by providing emergency response in the event of overdose, SIFs 
may reduce mortality associated with injection drug use. They suggest that SIFs 
may have potential as sites for HIV testing, in order to prevent further spread, 
monitor disease progression and provide access to treatment. They also suggest 
that it might be effective to incorporate other therapies into SIF facilities, such 
as methadone maintenance therapy, and assisted therapy for antiretroviral as 
well as tuberculosis medications 
There are methodological difficulties in 
demonstrating impacts of SIF use on the 
incidence of HIV infection 
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Zobel, F., & Dubois-Arber, F. (2004). 
Short appraisal of the role and 
usefulness of Drug Consumption 
Facilities (DCF) in the reduction of drug-
related problems in Switzerland: 
Appraisal produced at the request of the 
Swiss Federal Office of Public Health 
Lausanne: University Institute of Social 
and Preventative Medicine. 
* Morbidity 
* Mortality 
* Social/health care access 
* Injecting drug use 
* Public drug use 
* Publicly discarded syringes 
* Treatment initiation and 
outcomes 
Research up to 2004 
 
Worldwide 
This short appraisal report, commissioned by the Swiss Federal Office of Public 
Health, examines the Switzerland's drug policy and the use of SIFs and 
inhalation rooms, epidemiology of drug dependence in Switzerland, and 
evidence of efficacy with a focus on Switzerland. They conclude that SIFs and 
inhalation rooms achieve the objectives set for them, reducing risky behaviour, 
fatal overdoses, public order problems and access to social and healthcare 
services. They also state that there is limited evidence in some areas, but for the 
most part the overall effect of drug consumption rooms on health-related 
problems appears positive 
 
 
Independent Working Group. (2006). 
The Report of the Independent Working 
Group on Drug Consumption Rooms. 
York. 
* An environment for safer drug 
use 
* Health status of target group 
* Public disorder 
United Kingdom This comprehensive report from the Independent Working Group on Drug 
Consumption Rooms examines the policy context in the United Kingdom, the 
need for SIFs, evidence of efficacy (drawing largely on Hedrich 2004), potential 
barriers and concerns, models of SIF service and finally a set of 
recommendations. They recommend the establishment of SIF pilot schemes in 
the UK, as part of an integrated drug service, with strong community support 
and linkages. Conclude that SIFs offer a unique and promising way to work with 
the most problematic drug users, in order to reduce the risk of overdose, 
improve their health and lessen the damage and costs to society 
See Hedrich (2010, 2004) 
British Columbia Centre for Excellence in 
HIV/AIDS (2009). Findings from the 
evaluation of Vancouver’s pilot 
medically supervised safer injecting 
facility- Insite. Vancouver: British 
Columbia Centre for Excellence in 
HIV/AIDS. 
 
See also: 
 
Wood, E., Tyndall, M. W., Montaner, J. 
S., & Kerr, T. (2006). Summary of 
findings from the evaluation of a pilot 
medically supervised safer injecting 
facility. Canadian Medical Association 
Journal, 175, 1399—1404. 
*Promotion of illicit drug use 
*Initiation into treatment 
*Crime 
*Public order 
*Overdose prevention 
*Syringe sharing 
*Safe injecting practices 
 
Vancouver Provides a comprehensive summary of the research conducted on Vancouver’s 
SIF (see ‘Outcomes’ section for individual studies). Studies included in the 
review showed that the creation of Insite was associated with no substantial 
changes in drug use among IDUs; 1 person out of 1,065 reported their first 
injection at Insite. Individuals who used Insite at least weekly were 1.7 times 
more likely to enroll in a detox program than those who visited the centre less 
frequently, and the year after Insite opened, there was a 33% increase in 
detoxification service use. In terms of crime, a study found no statistically 
significant changes in rates of drug trafficking or assaults and robberies, and a 
statistically significant drop in vehicle break-ins and vehicle thefts.  
There were significant decreases in numbers of publicly discarded syringes, 
injection-related litter, and people injecting in the area around Insite. 
IDUs who use Insite to inject drugs are 70% less likely to share syringes than 
IDUs who do not use the facility, and consistent Insite users were almost 3 times 
more likely to use sterile water, 2.8 times more likely to swab injection sites,  
more than twice as likely to dispose of syringes safely, and 2.8 times  
more likely to cook or filter their drugs. 
Limitations of individual studies are 
described in published papers.  
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Table 2: Outcome evaluations and epidemiological studies (n=29 papers) 
 
Authors & Publication Year Outcomes Examined Study period 
& location 
Aim/Description Findings Unresolved Issues/ Notable Limitations 
DeBeck et al. (2011). Injection 
drug use cessation and use of 
North America's first medically 
supervised safer injecting 
facility. Drug and Alcohol 
Dependence, 113, 172-176. 
 
* Injecting drug use 
cessation 
* Treatment initiation 
Dec 2003- Jun 
2006 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
quitting drug use. Performed linkages with 
health databases to verify participant 
information 
Regular use of the SIF and having contact with counsellors 
at SIF were associated with entry into treatment (AHR = 
1.33, 95% CI: 1.04–1.72 for regular use of SIF). Entry into 
treatment programs was unsurprisingly associated with 
injection cessation 
Drug use cessation was in a short 
timeframe (6 months), potentially leading 
to an overestimation of cessation. Regular 
SIF use was defined somewhat arbitrarily 
and with no justification as at least one visit 
per week vs. less than one visit per week. 
Different definitions may have led to 
different results 
Marshall, B. D. L., Milloy, M. J., 
Wood, E., Montaner, J. S. G., & 
Kerr, T. (2011). Reduction in 
overdose mortality after the 
opening of North America's 
first medically supervised safer 
injecting facility: a 
retrospective population-
based study. The Lancet, 
377(9775), 1429-1437. 
* Fatal overdoses Jan 2001- Dec 
2005 
 
Vancouver 
This study examined the effect of opening the 
SIF on overdose mortality rates with a pre- and 
post- test design studying the area around the 
SIF (500m radius). Importantly, this study used a 
comparator; the city area not including the area 
around the SIF 
They found a decrease of 35% in overdose mortality in the 
area around the SIF following its opening. This was in 
comparison to the rest of the city, which saw a 9.3% 
decrease  
See Christian et al (2011) and Marshall, 
Milloy, Wood, Montaner & Kerr (2012) for 
critique and further comments 
KPMG. (2010). Further 
evaluation of the Medically 
Supervised Injecting Centre 
during its extended trial period 
(2007-2011): Final report. 
Sydney: KPMG. 
* Client/staff 
perspectives 
* Referral  
* Changes in injecting 
behaviour 
* Publicly discarded 
syringes 
* Public drug use 
* Community views on 
amenity 
* Opioid- related 
overdose events 
* Notifications of HIV 
and HCV infection 
Jun 2007- Apr 
2010 
 
Sydney 
This comprehensive report is an evaluation of 
the SIF in Sydney as of 2007 (extended trial 
period). It evaluates the SIF's performance on a 
number of outcome variables. It also includes a 
large set of descriptive data on client 
characteristics, SIF services and drug use 
* Generally positive perspectives and satisfaction by both 
clients and staff 
* New referral mechanisms indicate higher drug treatment 
referral uptake (see Kimber et al. 2008 for previous results) 
* More frequent SIF attendees were more likely to have 
accepted a referral to another service 
* Clients generally believed the SIF had improved their safe 
injecting practices 
* There has been a decline in total number of publicly 
discarded syringes in the SIF area, more marked in the 
areas within 500m of the SIF 
* There was some evidence that SIF users injected in 
public less often since attending the SIF 
* Community support for the SIF has increased over time 
* Larger decrease in opioid-related ambulance call outs 
and ER presentations in the SIF area versus the 
comparator group/s. No significance testing. See Salmon, 
van Beek, Amin, Kaldor & Maher (2010) and NCHERC 
(2007) for related analyses 
* Inconclusive results on HIV and HCV infection 
It is unclear whether many of the analyses 
have been subjected to statistical 
significance testing 
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Salmon, A. M., Van Beek, I., 
Amin, J., Kaldor, J., & Maher, L. 
(2010). The impact of a 
supervised injecting facility on 
ambulance call-outs in Sydney, 
Australia. Addiction, 105(4), 
676-683. 
* Opioid-related 
overdoses attended 
by an ambulance 
May 1998- 
May 2006 
 
Sydney 
Examined ambulance attendances in the 
immediate area around the SIF (3.6km2) pre- and 
post- the SIF opening. Importantly, this study 
used comparator groups; the rest of NSW and 
also the broader neighbouring area around the 
SIF 
There was a greater decline in opioid-related overdose 
ambulance attendances in the area around the SIF 
following its opening, versus the rest of NSW. This effect 
was significantly greater during the operating hours of the 
SIF and in the immediate area of the SIF (compared to the 
neighbouring area)- 80% versus 45%. They suggest that 
SIFs are likely to be more effective when located in areas 
of highly-concentrated drug use 
Overcomes the challenge of a true 
comparator with the ecological analysis 
Bravo, M. J., Royuela, L., De la 
Fuente, L., Brugal, M. T., 
Barrio, G., Domingo-Salvany, 
A., & the Itínere Project, G. 
(2009). Use of supervised 
injection facilities and 
injection risk behaviours 
among young drug injectors. 
Addiction, 104(4), 614-619. 
* Risky injecting 
behaviours 
2002- 2005 
 
Spain (5 SIFs) 
This study used a cross-sectional design with 
targeted sampling of general injecting drug users 
(SIF and non SIF) in Barcelona and Madrid. They 
sought to examine the use of SIFs as a predictor 
of safer injecting practices to prevent 
transmission of blood-borne infections 
SIFs users were more likely than non-SIFs users to be men, 
with marginal or illegal activities as the main source of 
income, and to be Hepatitis-C positive. Using SIFs was 
associated independently with not borrowing used 
syringes (AOR 0.4, 95% CI 0.2–0.9). However, there was no 
sig association between SIF use and not sharing injection 
equipment indirectly (AOR  0.7, 95% CI 0.4–1.4). These 
results suggest that more SIF efforts should be targeted at 
emphasising the relationship between indirectly sharing 
injection equipment and blood-borne virus infections 
Cross sectional study meaning no casual 
inferences were made. The 
representativeness of the sample is not 
known 
Marshall, B. D. L., Wood, E., 
Zhang, R., Tyndall, M. W., 
Montaner, J. S. G., & Kerr, T. 
(2009). Condom use among 
injection drug users accessing 
a supervised injecting facility. 
Sexually Transmitted 
Infections, 85(2), 121-126. 
* Condom use during 
intercourse in the past 
6 months 
Dec 2003- 
Dec 2005 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
condom use. This was a prospective longitudinal 
design to assess changes over time 
Over the 2 years, consistent condom use by SIF users 
increased by 13%-30%. Consistent condom use among 
regular partners was independently associated with time 
since recruitment from within the SIF (AOR 1.29, 95% CI 
1.06-1.55) and HIV positivity (AOR= 2.23, 95% CI 1.51-
3.31), but inversely associated with enrolment in 
alcohol/drug treatment (AOR 0.68, 95% CI 0.52-0.89) and 
injecting with a sex partner (AOR 0.5, 95% CI 0.37-0.68). 
For those reporting casual sex partners, consistent 
condom use was significantly associated with HIV positivity 
(AOR 1.70, 95% CI 1.03-2.81), borrowing syringes (AOR 
0.54, 95% CI 0.32-0.91) and lending syringes (AOR 0.52, 
95% CI 0.32-0.84) 
There was a large loss to follow-up. 
Measures relied on self-report of sexual 
encounters and may have led to 
underreporting of socially undesirable 
activities 
Kimber, J. O., Mattick, R. P., 
Kaldor, J., Van Beek, I., 
Gilmour, S., & Rance, J. A. 
(2008). Process and predictors 
of drug treatment referral and 
referral uptake at the Sydney 
Medically Supervised Injecting 
Centre. Drug and Alcohol 
Review, 27(6), 602-612. 
* Service referrals 
(e.g., treatment, 
health, welfare) 
* Service referral 
uptake (where the 
referral resulted in an 
assessment) 
May 2001- 
Oct 2002 
 
Sydney 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
referral to services. Referral uptake was defined 
as the proportion of people who followed 
through on referrals relative to total referrals 
made. Frequent attendance was defined as 
being in the top quartile of the visits’ frequency 
distribution during the study period (i.e. ≥12 
visits) 
There was a high rate of referral (24 per 1000 visits), 
mostly to drug treatment. Confirmed referral uptake, 
however, was greatest for health care referrals (27%). 
Frequent SIF uses were referred to drug treatment at more 
than 1.5 times the rate of other clients but actual uptake 
rates were not significantly different to others (OR 0.8, 
95% CI 0.4 – 2.0). Higher drug referral uptake was 
associated with sex work (AOR 2.6, 95% CI 1.1–5.8) and 
daily or more frequency of injecting (AOR 2.3, 95% CI 1.1 – 
5.2). Lower uptake was related to psychiatric history (AOR 
0.2, 95% CI 0.5 – 0.7). Also, they noted that over half of 
referral uptakes were to a nearby health/ treatment 
service, signalling the importance of integrated services 
Stringent referral variable- written referral 
only- may have resulted in a conservative 
estimate of referral uptake. Also, did not 
include dynamic factors that have an 
impact on referral uptake (e.g., client 
motivation and readiness to change, 
social/support networks) 
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Milloy, M.-J. S., Kerr, T., 
Mathias, R., Zhang, R., 
Montaner, J. S., Tyndall, M., & 
Wood, E. (2008). Non-Fatal 
Overdose Among a Cohort of 
Active Injection Drug Users 
Recruited from a Supervised 
Injection Facility. The 
American Journal of Drug and 
Alcohol Abuse, 34(4), 499-509. 
* Non-fatal overdoses Dec 2003- 
Dec 2005  
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
non-fatal overdose 
Factors independently associated with non-fatal overdose 
included sex trade involvement (AOR 1.45, 95% CI 1.07–
1.99), public drug use (AOR 1.50, 95% CI 1.09–2.06), being 
a victim of abuse (AOR 1.45, 95% CI 1.13–1.87), and 
needing help injecting (AOR 1.35, 95% CI 1.04–1.75). 
Methadone maintenance therapy was protective for non-
fatal overdose (AOR 0.68, 95% CI 0.49–0.94). There was no 
statistical evidence linking use of the SIF with a higher 
likelihood for non-fatal overdose (AOR 1.01, 95% CI 0.77–
1.32), even though previous studies indicate that more 
regular users of the SIF may carry more risk factors for 
overdose 
Limitations include unquantifiable potential 
changes in IDUs injecting routines. 
Recruitment into the study occurred after 
visits to the SIF had begun, which could 
have led to an underestimation of the SIF's 
effect 
Milloy, M. J., Kerr, T., Tyndall, 
M., Montaner, J., & Wood, E. 
(2008). Estimated drug 
overdose deaths averted by 
North America's first 
medically-supervised safer 
injection facility. PloS one, 
3(10), e3351. 
* Number of overdose 
deaths averted in the 
SIF 
Mar 2004- Jul 
2008 
 
Vancouver 
Used a Monte Carlo simulation and a three-part 
sensitivity analysis in order to obtain an estimate 
of the number of fatal overdoses averted by the 
SIF 
Number of overdose deaths averted in the SIF during the 
study period was equal to between two and 12 per annum. 
This represents between 6.1%-37% of the total overdose 
burden in the area during the study period 
Estimates were used for missing data 
Richardson, L., Wood, E., 
Zhang, R., Montaner, J., 
Tyndall, M., & Kerr, T. (2008). 
Employment Among Users of a 
Medically Supervised Safer 
Injection Facility. The 
American Journal of Drug and 
Alcohol Abuse, 34(5), 519-525. 
 
* Employment Dec 2003- 
Dec 2005 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
employment. Employment was defined as a self 
reported job in the last 6 months 
Factors that were negatively and independently associated 
with employment were being female (AOR 0.26, 95% CI 
0.18–0.37), Aboriginal (AOR 0.56, 95% CI 0.40–0.80), lower 
education (AOR 0.63, 95% CI 0.50–0.81), unstable housing 
(AOR 0.58, 95% CI 0.47–0.71), and daily heroin use (AOR 
0.81, 95% CI 0.66–0.99). Binge drug use was positively 
associated with employment (AOR 1.27, 95% CI 1.06–
1.52). There was no significant relationship between 
regular use of the SIF and employment, suggesting that 
regular use of the SIF neither interferes with nor promotes 
facility users’ employment  
The employment variable was very broad. 
Also, reliance on self report may have led to 
socially desirable reporting biases 
McKnight, I., Maas, B., Wood, 
E., Tyndall, M. W., Small, W., 
Lai, C., Montaner, J., & Kerr, T. 
(2007). Factors associated with 
public injecting among users 
of Vancouver's supervised 
injection facility. The American 
Journal of Drug and Alcohol 
Abuse, 33(2), 319-325. 
* Public drug use Jun 2004- Jul 
2005 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
public drug use. Also examined a range of other 
factors thought to be related to public drug use 
Frequency of SIF use was not associated with public drug 
use. Participants who reported that wait times affected 
frequency of SIF use were significantly more likely to 
report public drug use (AOR= 3.26, 95% CI 2.11–5.06). 
Other variables significantly and independently associated 
with public drug use were homelessness (AOR= 3.1, 95% CI 
1.46–6.58), recent incarceration (AOR= 1.77, 95% CI 1.15–
2.73), used needle lending (AOR= 5.39, 95% CI 1.96–
14.78), requiring help injecting (AOR= 1.60, 95% CI 1.01–
2.54), and daily heroin injection (AOR= 2.71, 95% CI 1.84–
3.98) 
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National Centre in HIV 
Epidemiology and Clinical 
Research. (2007). Sydney 
Medically Supervised Injecting 
Centre evaluation report no. 4: 
Evaluation of service operation 
and overdose-related events. 
Sydney: UNSW. 
* Opioid-related 
overdoses attended 
by an ambulance 
* Opioid-related 
deaths 
* Opioid poisoning 
presentations at 
hospitals 
* Publicly discarded 
syringes 
* Operating costs 
* Overdose-
related 
events: May 
1998- Apr 
2006 
* Syringe 
disposal: Jan 
2000- Jan 
2007. 
This report is the final evaluation issued by the 
NCHECR of the Sydney SIF. Includes results from 
Salmon, van Beek, Amin, Kaldor & Maher (2010) 
regarding ambulance call outs to opioid 
overdoses. Also reports on opioid-related 
deaths, conducting a similar analysis (pre- and 
post-SIF opening changes with comparison 
area).  They also examine changes in opioid 
poisoning presentations at Emergency 
Departments over the time period. Lastly, the 
authors analyse monthly counts of publicly 
discarded syringes pre- and post- the SIF 
opening 
There were significant decreases in monthly average 
morphine deaths in both the Kings Cross vicinity and the 
rest of NSW following the SIF opening; the difference 
between the rates of change was not significant (Poisson 
regression X2= 0.02, p= 0.877). There was a significant 
decrease in average monthly presentations to ERs in Kings 
Cross following the opening of the SIF (OR 0.65, 95% CI 
0.57–0.74), however no comparison group was used here. 
Lastly, there was a significant 48% decrease in the average 
monthly count of publicly discarded syringes in the vicinity 
of the SIF following its opening ()OR 0.52, 95% CI 0.51–
0.52). See Salmon, van Beek, Amin, Kaldor (2010) for more 
detailed results on ambulance call outs, which did suggest 
a possible effect of the SIF. Also includes operating costs of 
the SIF, which increased from previous estimates 
Socially desirable responding may have 
influenced results. The use of the postcodes 
2011 and 2010 to define the Kings Cross 
vicinity may be overly inclusive, leading to 
an underestimation of effect. Analysis of 
opioid poisoning hospital presentations 
limited by potential confounding 
introduced by the reduction in heroin 
supply around the same time the SIF was 
opened 
National Centre in HIV 
Epidemiology and Clinical 
Research. (2007). Sydney 
Medically Supervised Injecting 
Centre Interim Evaluation 
Report no. 3: Evaluation of 
Client Referral and Health 
Issues. Sydney: UNSW. 
* Self reported 
changes in risky 
injecting behaviour 
* Frequency of 
injecting 
* Heroin use 
* Public injection 
* Syringe sharing 
1995- 2005 
 
Sydney 
This report is an interim evaluation of the SIF in 
Sydney as of 2007. It evaluates the SIF's 
performance on some outcome variables. It also 
includes a large set of descriptive data on client 
characteristics, service use, referrals, and client 
health and risk behaviours 
77% of participants reported improvements in their 
injecting practices since registering at the SIF. Specifically, 
clients reported improvements in injecting technique, 
understanding of overdose risk and a decrease in the 
likelihood of sharing injecting equipment. A comparison of 
reported daily injecting from 2001 to 2004 among recent 
SIF attendees showed a significant trend downwards over 
time (p= 0.02) whereas the non-recent SIF attendees did 
not show any significant changes. Also, there was a 
significant increase in recent heroin injection among non-
recent SIF attendees (p= 0.04), whereas the recent SIF 
attendees showed no changes. Evidence about public 
injecting change was inconclusive, although recent SIF 
attendees consistently reported this more frequently. 
Lastly, there were no changes in syringe-sharing for any of 
the participants over time, with similar rates reported by 
recent and non-recent SIF attendees 
The cross-sectional nature of the 
information on changes in risky injecting 
behaviour must be taken with caution. 
Also, differences between the recent and 
non-recent SIF attendees in the subsequent 
analyses were not compared statistically 
Petrar, S., Kerr, T., Tyndall, M. 
W., Zhang, R., Montaner, J. S. 
G., & Wood, E. (2007). 
Injection drug users' 
perceptions regarding use of a 
medically supervised safer 
injecting facility. Addictive 
Behaviors, 32(5), 1088-1093. 
* Self reported 
changes in injecting 
behaviour 
* Barriers to use of the 
SIF 
Dec 2003- 
Sep 2005 
 
Vancouver 
This study assessed IDUs' experiences and 
opinions regarding the SIF in Vancouver and 
explored what kinds of operational changes 
might improve the current service 
75% of participants reported that their injecting behavior 
had changed since using the SIF, and 95% rated the overall 
quality of service as excellent or good. HIV-positive 
individuals were less likely to report behavior changes as a 
result of SIF use (p=0.005); this was likely due to safer 
baseline behaviors among this population. Commonly 
reported restrictions to using the SIF were travel 
difficulties (12%), limited operating hours (7%), waiting 
times (5%), and police working too near the SIF (5%). 
Potential changes in the SIF's operation were suggested. In 
relation to operational changes that would improve the 
current service, the three most common suggestions were 
longer hours of operation (53%), addition of a washroom 
(51%), and reduced waiting times (46%) 
As this study does not provide a robust test 
of injecting behaviour changes, the more 
relevant results are those pertaining to 
perceived barriers and improvements to 
the SIF rather than the changes in 
behaviour variable 
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Salmon, A. M., Thein, H.-H., 
Kimber, J., Kaldor, J. M., & 
Maher, L. (2007). Five years 
on: What are the community 
perceptions of drug-related 
public amenity following the 
establishment of the Sydney 
Medically Supervised Injecting 
Centre? International Journal 
of Drug Policy, 18(1), 46-53. 
Community 
perceptions of: 
* Public drug use 
* Publically discarded 
syringes 
* Drug dealing 
 
* Annoyances 
associated with public 
drug use 
* Advantages/ 
disadvantages of SIF 
Oct 2000- 
Nov 2005 
 
Sydney 
A survey was conducted among random samples 
of residents and business operators in Kings 
Cross prior to and following the opening of the 
SIF, to assess changes in community perceptions 
of public amenity 
There were downwards trends in perceived public drug 
use in both the residential and business samples, although 
the change was considered an independent effect only for 
the residential sample, after adjustment for confounds 
(AOR 0.53, 95% CI 0.37–0.74). There were also decreases 
in discarded syringes in both samples, which were both 
significantly and independently predicted by survey year 
(residential AOR 0.35, 95% CI 0.26–0.48; business AOR 
0.53, 95% CI 0.34–0.81). Perceptions of drug dealing were 
stable across the time period. Reported annoyances 
decreased significantly over the time period. Both 
residential and business operators reported more 
advantages than disadvantages of the SIF; advantages 
were health related (e.g., HIV/AIDS control, overdose risk) 
whereas disadvantages were concerns about increased 
drug use (e.g., attracts drug users to the area, encourages 
drug use). For many of the above measures, living within 
500m of the SIF decreased the likelihood of perceiving 
problems 
Supersedes Thein, Kimber, Maher, 
MacDonald & Kaldor (2005) in the two 
variables 'annoyances' and 
'advantages/disadvantages'. However, the 
responses to these outcomes appear to 
have been prompted in the 2005 study but 
unprompted here (i.e., in the previous 
study, the authors listed the 'impacts' of 
the SIF and asked for 
agreement/disagreement, whereas in the 
current study participants were asked to 
identify potential responses) 
Stoltz, J.-A., Wood, E., Small, 
W., Li, K., Tyndall, M., 
Montaner, J., & Kerr, T. (2007). 
Changes in injecting practices 
associated with the use of a 
medically supervised safer 
injection facility. Journal of 
Public Health, 29(1), 35-39. 
* Safer injection 
practices 
July 2004-
June 2005 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
safer injecting practices. There was no pre- post- 
test measure but instead, change was assessed 
by asking participants if they believed their 
injecting practices had changed since using the 
SIF 
Consistent SIF users were more likely than non-consistent 
SIF users to be using heroin daily and be involved in sex 
work. Each change in injection behaviour was 
independently and positively associated with consistent 
SIF use:  
* reuse syringes less often (AOR 2.04, 95% CI 1.38–3.01) 
* less rushed during injection (AOR 2.79, 95% CI 2.03–3.85) 
* less injecting outdoors (AOR = 2.7, 95% CI = 1.93–3.87) 
* using clean water for injecting (AOR 2.99, 95% CI 2.13–
4.18) 
* cooking or filtering drugs prior to injecting (AOR 2.76, 
95% CI 1.84–4.15) 
* tying off prior to injection (AOR 2.63, 95% CI 1.58–4.37) 
* safer disposal of syringes (AOR 2.13, 95% CI 1.47–3.09) 
* easier finding a vein (AOR 2.66, 95% CI 1.83–3.86) 
* injecting in a clean place (AOR 2.85, 95% CI 2.09–3.87) 
Non-significant associations between 
consistent SIF use and borrowing (OR 0.78, 
95% CI 0.42–1.44), and lending (OR 0.63, 
95% CI 0.36–1.10) syringes (Table 1). 
Measures rely on self-report 
Wood, E., Tyndall, M. W., 
Zhang, R., Montaner, J. S. G., & 
Kerr, T. (2007). Rate of 
detoxification service use and 
its impact among a cohort of 
supervised injecting facility 
users. Addiction, 102(6), 916-
919. 
* Detox service use 
* Treatment initiation 
Dec 2003- 
Mar 2005 
(Follow up 
Jun 2005) 
 
Vancouver 
This study examined the effect of opening the 
SIF on detox service use with a pre- and post- 
test design studying SIF users. The study 
conducts prospective and retrospective 
database linkages with detox facilities rather 
than self-report 
The year after the SIF opened was associated with a 30% 
increase in uptake of detox services (AOD 1.32, 95% CI 
1.11–1.58). At follow up, detox service use was positively 
associated with uptake of methadone maintenance 
therapy (AHR 1.56, 95% CI 1.04–2.34) or other treatment 
(AHR 3.73, 95% CI 2.57–5.39). Furthermore, use of the SIF 
decreased significantly following detox (24 visits versus 19 
visits per month, p= 0.002) 
Differences in detoxification use between 
the pre- and post-SIF years could have been 
attributable to unmeasured factors 
independent of the SIF 
Kerr, T., Stoltz, J.-A., Tyndall, 
M., Li, K., Zhang, R., Montaner, 
J., & Wood, E. (2006). Impact 
of a medically supervised safer 
injection facility on community 
drug use patterns: a before 
and after study. BMJ, 
332(7535), 220-222. 
Starting and stopping: 
* Injecting drug use 
* Binge drug use 
* Crack cocaine 
smoking 
* Starting or stopping 
methadone 
Period 1 
(2002-2003) v 
period 2 
(2003-2004)  
 
Vancouver 
This longitudinal study examined the effect of 
opening the SIF on drug use patterns with a pre- 
and post- test design studying IDU in Vancouver. 
Specifically, the Comparing % change in 
variables pre/post SIF opening. From Vancouver 
injecting drug users study (VIDUS) 
Only differences were: decrease in number of participants 
who relapsed into binge drug use in the second period, 
and in increase in number who started smoking crack 
cocaine 
These were a set of early results, many of 
which have been supersedes by later 
studies 
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National Centre in HIV 
Epidemiology and Clinical 
Research. (2006). Sydney 
Medically Supervised Injecting 
Centre Interim Evaluation 
Report no. 2: Evaluation of 
Community Attitudes towards 
the Sydney MSIC. Sydney: 
UNSW. 
Community 
perceptions of: 
* Public drug use 
* Publically discarded 
syringes 
* Drug dealing 
* Annoyances 
associated with public 
drug use 
* Knowledge of SIF 
* Agreement with SIF 
* Advantages/ 
disadvantages of SIF 
2000-2005 
 
Sydney 
This report is an interim evaluation of the SIF in 
Sydney as of 2006. It asses attitudes towards 
drug use and SIFs, experience and perceptions of 
public drug use and related issues 
Rates of knowledge of the location of the SIF stayed fairly 
constant over time. The proportions of residents who 
agreed with the establishment of the SIF in 2005 was 73%, 
a slight decline from 78% in 2002, but still above the 
proportion who agreed with its establishment prior to 
opening in 2000 (68%). 
See Salmon, Thein, Kimber, Kaldor & Maher (2007) for 
other results 
Supersedes Thein, Kimber, Maher, 
MacDonald & Kaldor (2005) on variables 
'knowledge of SIF' and 'agreement with SIF' 
Wood, E., Tyndall, M. W., 
Zhang, R., Stoltz, J.-A., Lai, C., 
Montaner, J. S. G., & Kerr, T. 
(2006). Attendance at 
supervised injecting facilities 
and use of detoxification 
services. New England Journal 
of Medicine, 354(23), 2512-
2514. 
* Time to entry into a 
detox program 
Dec 2003- 
Mar 2005 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF to 
assess whether frequency of SIF use can predict 
entry into detox. Performed linkages with health 
databases to verify participant information 
Factors that were independently associated with more 
rapid entry into detox were homelessness (AHR 1.42, 95% 
CI 1.06–1.90), treatment history (AHR 2.43, 95% CI 1.41–
4.22), and having contact with the facility's counsellor 
(AHR 1.98. 95% CI 1.26–3.10). Weekly or more frequent 
use of the SIF was also independently associated with 
more rapid entry into detox (ARH 1.72, 95% CI 1.25–2.38) 
Does not address detoxification success, 
only enrolment. Also this may not mean 
they end up in treatment, or succeed there 
either 
Wood, E., Tyndall, M., Lai, C., 
Montaner, J., & Kerr, T. (2006). 
Impact of a medically 
supervised safer injecting 
facility on drug dealing and 
other drug-related crime. 
Substance Abuse Treatment, 
Prevention, and Policy, 1(1), 
13. 
* Crime rates 
(charges) 
Oct 2003- Sep 
2005 
 
Vancouver 
This study examined the effect of opening the 
SIF on crime with a pre- and post- test design 
studying crime rates in the neighbourhoods 
around the SIF. Accessed Vancouver Police 
Department statistics regarding charges for drug 
trafficking, assaults and robberies, and vehicle 
break-ins and vehicle theft 
Arrest for drug trafficking, assaults, and robbery were 
similar after the facility's opening. Rates of vehicle break-
ins/theft declined significantly 
Due to the nature of the methodology and 
the inability to rule out confounding factors 
such as policing practices, the authors 
caution against inferring that any changes 
were due to the SIF. They instead suggest 
that the SIF was not associated with a 
marked increase in drug-related criminal 
activity 
Freeman, K., Jones, C. G., 
Weatherburn, D. J., Rutter, S., 
Spooner, C. J., & Donnelly, N. 
(2005). The impact of the 
Sydney Medically Supervised 
Injecting Centre (MSIC) on 
crime. Drug and Alcohol 
Review, 24(2), 173-184. 
* Drug-related activity 
around the MSIC 
(loitering, dealing)  
* Acquisitive crime 
Jan 1999- Oct 
2002 
 
Sydney 
This study conducts a time series analysis of 
police-recorded trends, as well as key informant 
interviews, in order to examine the Sydney SIF's 
impact on crime. They concentrate on the area 
surrounding the SIF 
They find no evidence the SIF had any impact on 
acquisitive crime. There was little or no sustained increase 
in loitering near the SIF by drug users or dealers 
Results may be confounded by the heroin 
shortage 
Kerr, T., Tyndall, M., Li, K., 
Montaner, J., & Wood, E. 
(2005). Safer injection facility 
use and syringe sharing in 
injection drug users. The 
Lancet, 366(9482), 316-318. 
* Syringe sharing Dec 2003- 
June 2004 
 
Vancouver 
Used a cohort of IDUs recruited from the 
community (VIDUS study) and measured their 
frequency of use of the SIF to assess whether 
frequency of SIF use can predict syringe sharing 
Use of the SIF was independently associated with reduced 
syringe sharing (AOR 0.29, 95% CI 0.11–0.78). 
Furthermore, there were no baseline-pre SIF-syringe 
sharing differences between those reporting consistent 
and non-consistent use of the SIF, demonstrating that the 
groups were roughly equivalent in this respect and thus 
increasing confidence in the conclusion that SIF use was 
the cause of the effect 
Sample not random and may not be 
representative. Rates of syringe sharing 
may be undestimates because of socially 
desirable responding. Used a combined 
endpoint of lending and borrowing to 
obtain adequate statistical power 
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Thein, H.-H., Kimber, J., 
Maher, L., MacDonald, M., & 
Kaldor, J. M. (2005). Public 
opinion towards supervised 
injecting centres and the 
Sydney Medically Supervised 
Injecting Centre. International 
Journal of Drug Policy, 16(4), 
275-280. 
Community 
perceptions: 
* Knowledge of SIF 
* Agreement with SIF 
* Understanding of 
impacts 
*SIF location 
considerations 
Oct 2000- Oct 
2002 
 
Sydney 
A survey was conducted among random samples 
of residents and business operators in Kings 
Cross prior to and following the opening of the 
SIF, to assess changes in community perceptions 
of the SIF 
Most respondents reported some knowledge of SIFs. 
There was an increase in agreement with the 
establishment of the SIF from 68% in 2000 to 78% in 2002 
(p< 0.001) and a corresponding decrease in disagreement 
(26% to 17%, p< 0.001). There were significant decreases 
for both residents and business operators in the beliefs 
that SIFs make drug law enforcement difficult, and that 
SIFs make people think it's legal to inject drugs. There 
were significant increases in the beliefs that SIFs improve 
the health of users and reduce publicly discarded syringes. 
Overall the findings indicate diminished concern among 
local residents and businesses about crime and drug users 
in the area after the SIF opened. The three most frequently 
reported locations by respondents in 2000 and 2002 were 
areas of high drug use, away from children and young 
people and away from residential areas 
Despite evidence of a decrease, the authors 
do not address the high agreement with 
the beliefs 'SIFs attract drug users' and 'SIFs 
make people think injecting drug use is 
legal'. Also see Salmon, Thein, Kimber, 
Kaldor & Maher (2007) for related study 
Wood, E., Tyndall, M., W. , 
Stoltz, J.-A., Small, W., Lloyd-
Smith, E., Zhang, R., . . . Kerr, 
T. (2005). Factors Associated 
with Syringe Sharing Among 
Users of a Medically 
Supervised Safer Injecting 
Facility. American Jounral of 
Infectious Diseases, 1(1) 
* Syringe lending and 
borrowing 
Mar 2004- 
Oct 2004 
 
Vancouver 
Used a cohort of IDUs recruited from the SIF and 
measured their frequency of use of the SIF 
(comparing those who used the SIF exclusively 
for all their injections to those who also injected 
elsewhere) to assess whether frequency of SIF 
(and what other factors) use can predict safer 
syringe lending and borrowing among SIF users. 
Examined both HIV-positive and negative SIF 
users 
Syringe borrowing among HIV-negative IDUs was positively 
associated with public drug use (OR 7.07, 95% CI 2.16–
23.13) and requiring help injecting (OR 2.59, 95% CI 1.42–
4.74). Syringe lending among HIV-positive IDUs was 
associated with daily cocaine injection (OR 3.42, 95% CI 
1.15–10.2) and shooting gallery use (OR 6.16, 95% CI 1.75–
21.70). There was some evidence that the SIF may reduce 
syringe borrowing among HIV-negative IDUs (OR 0.14, 95% 
CI 0.00–0.78), but no evidence that the SIF may reduce 
syringe lending among HIV-positive IDUs (OR 0.94, 95% CI 
0.00–7.90) 
The analyses were bivariate rather than 
multivariate; i.e., they did not adjust scores 
to determine independent effect of each 
factor. For example, the effect found due to 
SIF use could have disappeared when 
controlling for differences in another factor 
 
 
Wood, E., Kerr, T., Small, W., 
Li, K., Marsh, D. C., Montaner, 
J. S. G., & Tyndall, M. W. 
(2004). Changes in public 
order after the opening of a 
medically supervised safer 
injecting facility for illicit 
injection drug users. Canadian 
Medical Association Journal, 
171(7) 
* Public injecting drug 
use  
* Publicly discarded 
syringes 
* Injection-related 
litter 
*Drug dealers in 
vicinity 
Aug 2003- 
Dec 2003 
 
Vancouver 
This study examined the effect of opening the 
SIF on public order with a pre- and post- test 
design studying the area surrounding the SIF (10 
city blocks). The study used objective outcome 
measures and data was collected by 
observation. Difference between 6 wks before 
SIF opening and 12 wks after SIF opening (daily 
averages) 
There were statistically significant correlations between 
daily counts of SIF usage and daily counts of the 3 public 
order measures. The daily mean number of suspected drug 
dealers was 45.2 in the period before and 40.7 in the 
period after the opening of the SIF; the difference was not 
statistically significant (p= 0.34). The period after the 
opening of the SIF was independently associated with a 
reduction in public injection drug use (β= –0.61, p< 0.001), 
publicly discarded syringes (β= –0.72, p< 0.001) and 
injection-related litter (β= –0.72, p < 0.001) 
Did not adjust results for seasonality. There 
was a possibility of observer bias in the 
data collection phase.  
MSIC Evaluation Committee. 
(2003). Final report of the 
evaluation of the Sydney 
Medically Supervised Injecting 
Centre. Sydney. 
* Opioid-related 
overdoses attended 
by an ambulance 
* Opioid poisoning 
presentations at 
hospitals 
* Opioid-related 
deaths 
* Publicly discarded 
syringes 
* Overdose deaths 
prevented 
* New cases of HIV, 
HBV and HCV 
* Incidence of HCV 
Various 
 
Sydney 
This comprehensive report is an evaluation of 
the SIF in Sydney as of 2003. It evaluates the 
SIF's performance on a number of outcome 
variables. It also includes a large set of 
descriptive data on client characteristics and use 
Although the same data sets were used in published 
individual studies, there is some difference in 
measurement/analysis, time period and level of detail 
between studies. It may be useful to review all relevant 
studies: 
* See NCHECR (2007) and Salmon, Van Beek, Amin, Kaldor 
& Maher (2010) for results on opioid overdose, although 
the current study does a very different analysis- time 
series- rather than odds ratios 
* See Kimber et al (2008) for results on client health and 
referral uptake. Differs in definition of 'frequent' SIF 
attendance. Consequently, there are different results. In 
the current article, clients who visited the SIF on more 
than 10 occasions were almost 18 times more likely to 
have confirmed referral uptake (OR 17.7, 95% CI 10.1–
See KPMG (2010) for results in the 
extended trial period (to 2007). Results may 
be confounded by the heroin shortage. SIF 
clients could not be followed up across time 
if they did not stay in contact with the SIF 
due to privacy legislation 
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* Prevalence of HIV 
and HCV 
* Health service 
referral uptake 
* Crime 
*Drug-related 
loitering 
30.9)  
* See Salmon, Thein, Kimber, Kaldor & Maher (2007), 
Thein, Kimber, Maher, MacDonald & Kaldor (2005) and 
National Centre in HIV Epidemiology and Clinical Research 
(2006) for results on public opinion/amenity  
* See Freeman et al (2005) for results on crime and 
loitering 
Zurhold, H., Degkwitz, P., 
Verthein, U., & Haasen, C. 
(2003). Drug consumption 
rooms in Hamburg, Germany: 
Evaluation of the effects on 
harm reduction and the 
reduction of public nuisance. 
Journal of Drug Issues, 33(3) 
* Drug consumption 
behaviour 
* Service use 
* Risk and health 
awareness 
* Stressors for staff 
* Community 
perceptions of 
nuisance and attitudes 
towards SIFs 
Unclear 
 
Germany (3 
SIFs) 
Examined whether use of SIFs leads to positive 
changes in health-related behaviours and public 
disturbances. The data on behaviour change is 
descriptive. Also conducted qualitative 
interviews with community members and 
analysed them using content analysis 
Most of the sample reported at least one change in health-
related behaviour. The most frequently-reported changes 
were 'more careful hygiene and cleanliness' (37%) and 
'taking more time and rest' (28%).  More frequent SIF users 
reported more changes in positive habits, using more 
services, having more public drug use, and spending more 
time in the open drug scene. Qualitative interviews 
indicated that most community members believed drug-
related burdens had declined since the opening of SIFs 
Little statistical significance testing, so the 
changes in injecting behaviours should be 
regarded as descriptive. Also note that 
these SIFs are rooms housed in broader 
'low threshold' facilities which offer many 
other services, and the rooms are open to 
both injecting and smoking drug users 
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Table 3: Economic assessments (n=7 papers) 
 
Authors & Publication Year Outcomes Examined Study period & 
location 
Aim/Description Findings Unresolved Issues/ Notable Limitations 
Andresen, M. A., & Boyd, N. 
(2010). A cost-benefit and 
cost-effectiveness analysis 
of Vancouver's supervised 
injection facility. 
International Journal of Drug 
Policy, 21(1), 70-76. 
* HIV infections 
prevented (lifetime 
health costs)  
* Deaths prevented (lost 
productivity/ wages)  
* Running costs of SIF 
Vancouver Conducted a cost-effectiveness and a cost-benefit 
analyses of the Vancouver Insite SIF to determine 
whether the facility’s prevention of infections and 
deaths among IDUs is of greater or lesser cost than 
the cost involved in providing the service 
The SIF prevents 35 new cases of HIV and 2.8 deaths per 
year. This results in societal benefits of $7.56m per year 
(after costs are taken into account). Therefore the Insite 
SIF is cost saving as a stand-alone operation, independent 
of Insite’s other services 
The economic evaluation is not 
methodologically rigorous. 
Methodological issues pertaining to 
models, data and assumptions are raised 
by Pinkerton (2011) 
Pinkerton, S. D. (2011). How 
many HIV infections are 
prevented by Vancouver 
Canada's supervised 
injection facility? 
International Journal of Drug 
Policy, 22(3), 179-183. 
* HIV infections 
prevented (lifetime 
health costs)  
* Deaths prevented (lost 
productivity/ wages)  
* Running costs of SIF 
Vancouver Suggest that Andresen & Boyd (2010) made many errors, including incorrect equations, misspecification of 
models, unjustified parameters and more. They identify the errors and suggest corrections to the model, 
resulting in a revised estimate of 5–6 HIV infections prevented by the SIF per year, which is about smaller than 
Andresen & Boyd's figure of 35 by roughly a factor of 5. The estimate Pinkerton gives here is higher than the 2.8 
figure in his 2010 paper (which includes a similar analysis) because the current paper takes an additional factor 
into consideration. Despite the corrections made to Andresen & Boyd's model, the author finds that the SIF is 
still cost-saving; the total savings due to averted HIV-related medical care costs and prevented overdose deaths 
(approximately $1.7 to $1.9 million per year), are just slightly greater than the estimated $1.5 million annual 
operating cost of the SIF 
This paper does not seek to conduct a 
cost-benefit or cost-effectiveness 
analysis, it provides corrections to an 
existing model 
Pinkerton, S. D. (2010). Is 
Vancouver Canada's 
supervised injection facility 
cost-saving? Addiction, 
105(8), 1429-1436. 
* HIV infections 
prevented (lifetime 
health costs)  
* Running costs of 
facility 
Vancouver The aim of the study was to estimate whether 
Vancouver's Insite facility (SIF and Needle 
Exchange Program (NEP)) prevented a sufficient 
number of HIV infections to be cost saving. A 
series of equations were used to estimate the 
expected incidence of HIV infection within 
Vancouver’s IDU community, both with and 
without the SIF in operation 
Found that Insite prevents 83.5 HIV infections per year, 
which equates to approximately $17.6m saving (they also 
give $7.8m as a conservative estimate) in life-time HIV-
related medical care costs. This exceeds the facility's 
operating costs ($3m annually), so Insite is cost-saving. This 
is mainly due to the NEP; the reduction in borrowing rates 
due to safe injections within the SIF prevented only 2.8 
infections per year averting $580 000 in additional HIV-
related medical care costs on top of the NEP. The NEP is 
considerably more beneficial than the SIF in reducing HIV 
infections. 
It is unclear whether the SIF itself is cost-
saving. See Pinkerton (2011) for a similar 
model looking only at the SIF. The 
authors acknowledge that the scarcity of 
detailed information about the injecting 
practices of IDUs in Vancouver impacts 
the certainty of findings 
Bayoumi, A. M., & Zaric, G. 
S. (2008). The cost-
effectiveness of Vancouver's 
supervised injection facility. 
Canadian Medical 
Association Journal, 179(11), 
1143-1151. 
* Deaths prevented (life-
years gained) 
* Rates of HIV and 
Hepatitis C infection  
* Healthcare costs 
Vancouver The authors used a dynamic compartmental 
model with a 10 year time horizon to conduct a 
cost-effectiveness analysis of the Vancouver SIF 
(SIF only, excluding Insite's other facilities). They 
modelled individuals aged 15–64 cycling 
through the model until death, ageing beyond 
64 years or migration out of the Vancouver area 
At their most conservative estimate, the SIF was associated 
with net savings (incremental gain relative to no SIF) of 
almost $14m and 920 life-years gained over the 10 years. 
The ratio for the SIF relative to no SIF dominated (the SIF is 
cost effective) 
Results were sensitive to rates of 
injecting and rates of needle sharing. See 
Des Jarlais, Arasteh & Hagan (2008) for 
comments 
Des Jarlais, D. C., Arasteh, K., 
& Hagan, H. (2008). 
Evaluating Vancouver's 
supervised injection facility: 
data and dollars, symbols 
and ethics. Canadian 
Medical Association Journal, 
179(11), 1105-1106. 
 See Bayoumi & Zaric 
(2008) 
Vancouver State that the Bayoumi & Zaric study overestimates incidence rate of HIV infection, leading to biased results. 
However, even with a revised estimate of about 250–350 averted HIV infections over 10 years, the SIF is still 
cost-effective. The authors conclude that the threat to close Insite appears to be based more on emotional and 
symbolic reactions to the facility than to evidence 
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Saha International Limited. 
(2008). Final Report to NSW 
Health 'Economic evaluation 
of the Medically Supervised 
Injecting Centre at Kings 
Cross (MSIC). Sydney: SAHA. 
* HIV/HCV infection 
prevented 
* Client & referral 
services 
* Overdoses prevented 
* Other agencies 
* Running costs of 
facility 
Sydney Conducts a cost-benefit analysis comparing  the 
estimated costs of running SIF against the costs 
of providing a similar health outcome elsewhere 
in the health system 
The SIF saves $658,000 over providing similar health 
outcomes, as currently achieved at SIF, through other 
means in the health system. Without the SIF, there would 
be significant costs in the treatment of overdoses and new 
HIV and HCV infections. This indicates that the health 
outcomes provided by the SIF come at a lower cost to 
Government than the alternative 
Sensitivity testing of key parameters 
demonstrated that more conservative 
estimates resulted in the SIF coming at a 
higher cost to Government than the 
alternative 
MSIC Evaluation Committee. 
(2003). Final report of the 
evaluation of the Sydney 
Medically Supervised 
Injecting Centre. Sydney. 
* Deaths prevented (lost 
productivity, lost quality 
of life) 
* Service utilisation 
(NEP, ambulance calls, 
Police) 
* Running costs of SIF 
Sydney Conducted a cost-benefit analysis of the Sydney 
SIF to determine whether the existence of the 
SIF is preferable to its non-existence 
Cost/benefit ratios for the future operation of the SIF could 
range from 1.20 to 1.97, indicating that it is cost-beneficial 
compared to the SIF not existing 
Does not include opportunity cost to the 
operation of the SIF (that is, the money 
used to operate the SIF could have been 
used to purchase other interventions). 
SAHA (2008) includes this factor. Also 
reports on various outcomes (see entry 
above) 
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Table 4: Policy and Law (n=15 papers) 
 
Authors & Publication Year Location Aim/Description and Findings 
Semaan, S., Fleming, P., Worrell, 
C., Stolp, H., Baack, B., & Miller, 
M. (2011). Potential role of safer 
injection facilities in reducing 
HIV and Hepatitis C infections 
and overdose mortality in the 
United States. Drug & Alcohol 
Dependence, 118, 11. 
United States The authors use the Kass ethical framework for public health programs to analyse health needs and outcomes, operational matters, and ethical considerations for SIFs in the 
U.S.. Public health goals include overdose mortality, and HIV/Hepatitis C infection. They review the evidence and conclude that SIFs should be considered by public health 
providers and policy makers 
Burris, S., Anderson, E. D., 
Beletsky, L., & Davis, C. S. (2009). 
Federalism, policy learning, and 
local innovation in public health: 
The case of the supervised 
injection facility. Saint Louis 
University Law Journal, 53 
United States This article explains the various mechanisms for authorizing an SIF under state law, the dual (state and federal) regulation of controlled substances in the United States, and 
then considers how a state would counter a federal challenge to a state-authorized SIF. The authors conclude by distinguishing evidence-based health policy from “policy 
learning,” where efficacy is a necessary but insufficient component of policy implementation. Real policy learning, which is more about providing a forum for the ongoing 
creation of consensual knowledge and agreed processes to guide policy, should not be forgotten in the case of the SIF 
Beletsky, L., Davis, C. S., 
Anderson, E., & Burris, S. (2008). 
The law (and politics) of safe 
injection facilities in the United 
States. American journal of 
public health, 98(2), 231-237. 
United States Discusses legal challenges with launching SIFs in the U.S.. Addresses two key legal issues: under which jurisdiction would a SIF be governed? And, how would a SIF be treated 
under federal law? They conclude that there is a difficult legal path for SIFs but potentially worthwhile. The authors describe possible legal steps to take in launching a SIF 
Hathaway, A. D., & Tousaw, K. I. 
(2008). Harm reduction headway 
and continuing resistance: 
Insights from safe injection in 
the city of Vancouver. 
International Journal of Drug 
Policy, 19(1), 11-16. 
 n.a. Explores the moral platform behind SIFs. The authors dispute the suggestion that harm reduction strategies are irresponsible, dishonest, or immoral. Instead they state that 
the stance of harm reduction is inherently a moralistic stance that weighs costs and benefits of drug use and intervention. They suggest that a past muted stance on moral 
justifications for harm reduction has for the most part been useful, or politically expedient, allowing for some common ground between parties by sidestepping ideological 
disputes. By neglecting its core values, however, harm reduction severely undermines its inherent humanism and basis in respect for human rights. They contend that these 
moral justifications should be further cultivated and promoted by proponents 
Wood, E., Kerr, T., Tyndall, M. 
W., & Montaner, J. S. G. (2008). 
The Canadian government's 
treatment of scientific process 
and evidence: Inside the 
evaluation of North America's 
first supervised injecting facility. 
International Journal of Drug 
Policy, 19(3), 220-225. 
Canada Reports the events around the Canadian government's rejection of the continuation of the Vancouver SIF study in 2006, following several years of its operation. The authors 
express concerns regarding the new Canadian federal government’s handling of scientific processes and disregard for the outcome of peer review recommendations. The 
authors call for greater public scrutiny of the new Canadian government’s handling of scientific evidence and wish to use the Canadian SIF experience as a lesson for 
researchers, drug policy-makers, and affected communities in other settings considering SIFs 
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Fischer, B., & Allard, C. (2007). 
Feasibility Study on ‘Supervised 
Drug Consumption’ Options in 
the City of Victoria Victoria: 
Centre for Addictions Research 
of British Columbia (CARBC), 
University of Victoria 
Canada This feasibility study was commissioned by the Vancouver Island Health Authority and the City of Victoria to facilitate the development of a possible SIF in an evidence-based 
and locally needs-responsive way for Victoria (Canada). Includes the epidemiology of drug use and harms in Victoria, the policy context, a review of SIF experiences 
worldwide, evidence for efficacy, and a stakeholder survey of attitudes, parameters and needs regarding SIF options in Victoria. They recommend that a SIF under a ‘low 
threshold’ service model be implemented, with the principal objective being to reduce health-related harms for IDUs; offered in close integration with a range of core 
additional health and social services; with a meaningful and active role to be played by community stakeholders and police 
Rhodes, T., Kimber, J., Small, W., 
Fitzgerald, J., Kerr, T., Hickman, 
M., & Holloway, G. (2006). Public 
injecting and the need for ‘safer 
environment interventions’ in 
the reduction of drug-related 
harm. Addiction, 101(10), 1384-
1393. 
 n.a. This commentary considers the micro injecting environment as a critical dimension of risk for IDUs, focusing on the importance of reducing public drug injecting in mediating 
risk. The authors raise a need for safer injecting environment interventions, including establishment of SIFs, making current injecting sites safer (e.g., equipment vending 
machines, improved hygiene in known injecting areas), and prevention through urban design. The authors conclude that SIFs should be accompanied by interventions 
embedded within existing sites, and caution against prevention through urban design as it may serve to displace and further marginalise IDUs 
Christie, T., Wood, E., Schechter, 
M. T., & O'Shaughnessy, M. V. 
(2004). A comparison of the new 
Federal Guidelines regulating 
supervised injection site 
research in Canada and the Tri-
Council Policy Statement on 
Ethical Conduct for Research 
Involving Human Subjects. 
International Journal of Drug 
Policy, 15(1), 66-73. 
Canada This commentary provides a critical analysis of the new Canadian Federal Guidelines regarding the legal basis for a SIF in Canada and compares them to the Tri-Council Policy 
Statement on Ethical Conduct for Research Involving Humans (TCPS), the established standards for scientific research ethics. The authors state that by giving a purely 
'scientific' justification for SIFs' legal exemption, the Canadian government should defer to the standards in the TCPS rather than the new Federal Guidelines 
Fischer, B., Turnbull, S., Poland, 
B., & Haydon, E. (2004). Drug 
use, risk and urban order: 
examining supervised injection 
sites (SISs) as 'governmentality'. 
International Journal of Drug 
Policy, 15(5-6), 357-365. 
 n.a. This paper examines SIFs under the socio-theoretical framework of 'governmentality' which shifts the definition and control of substance use from the traditional, punitive 
state basis to a self-governing drug user who manages his/her own risks. The authors propose that SIFs are best understood in the context of their aim of spatially regulating 
(concealing or displacing, rather than eliminating) the activities of IDUs. SIFs act as a disciplinary mechanism to shape an 'informed, responsibilised and well disciplined drug-
using agent' in an insidious post-modern form of social control that may serve to further repress some IDUs. The authors request decision-makers have a reflexive stance 
regarding these possibly counter-intuitive dimensions of SIFs 
Malkin, I., Elliott, R., & McRae, R. 
(Writers). (2003). Supervised 
injection facilities and 
international law, Journal of 
Drug Issues. Tallahassee, United 
States, Tallahassee. 
 n.a. This article considers the position of supervised injection facilities in international law. The authors state that under international legal obligations such as the legal 
imperative to act, to protect human life, and the right to the highest attainable standard of health, implementing SIFs is an appropriate measure. Further, they suggest that 
SIFs are permissible (i.e., not blocked) by international drug laws. The authors conclude that SIF trials should be implemented in other parts of the world, in accordance with 
ethical and legal obligations 
Broadhead, R. S., Kerr, T. H., 
Grund, J.-P. C., & Altice, F. L. 
(2002). Safer injection facilities 
in North America: Their place in 
public policy and health 
initiatives. Journal of Drug 
Issues, 32(1), 329-355. 
North America This commentary addresses several policy questions: What specific problems do SIFs address over other services in responding to drug-related harms? What agreements 
need to be considered and negotiated in order to implement an SIF within a municipality? What rules of operation do SIFs generally follow? They state that SIFs target 
several problems and that in order to successfully negotiate a SIFs' place in a community, the active involvement and support of law enforcement, city officials, drug 
assistance agencies, and injectors themselves is essential. They suggest that the time has come for more North American municipalities to begin considering SIFs, and to 
provide support for research of SIFs operating in IDU communities 
Elliott, R., Maklin, I., & Gold, J. 
(2002). Establishing safe 
injection facilities in Canada: 
Legal and ethical issues: 
Canadian HIV/AIDS Legal 
Network. 
Canada This feasibility study from the Canadian HIV/AIDS Legal Network, sought to contribute to the informed development of Canadian law and policy that supports harm-
reduction measures. Includes the epidemiology of drug use and harms in Canada, the policy/legal context, a review of SIF experiences worldwide,  arguments for/against 
SIFs (with evidence), and recommendations. They conclude that there are ethical and legal obligations to introduce SIFs in Canada and that the government should take the 
necessary measures to support this 
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Joint Select Committee into Safe 
Injecting Rooms. (1998). Report 
on the establishment or trial of 
safe injecting rooms. Sydney: 
Parliament of New South Wales. 
Australia This feasibility study followed the recommendation by the Royal Commission into the New South Wales Police Service in the 1990's in NSW. Includes the epidemiology of 
drug use, services and harms in NSW, a review of SIF experiences worldwide, evidence for efficacy, arguments for/against SIFs (with evidence), the policy/legal context in 
NSW, models of SIF service and recommendations. They recommend that the establishment or trial of a SIF not proceed due to: safety concerns associated with 
administering and operating injecting rooms; impact on the local community; increased crime risks; condones drug use; and that resources would be better directed to 
expanding the range and capacity of drug treatment. However, there were a number of Committee members who dissented. The Sydney SIF since this time has been 
established 
Jauncey, M. E., van Beek, I., 
Salmon, A. M., & Maher, L. 
(2011). Bipartisan support for 
Australia’s supervised injecting 
facility: A decade in the making. 
Medical Association Journal, 
195, 264. 
Australia This letter, marking ten years of the Sydney SIF’s operation, gives a brief update on recent political events. Whilst public and medical opinion has been in support of SIFs, 
there has been entrenched political opposition, that has only recently been defeated. 
Skretting, A., & Olsen, H. (2008). 
The Norwegian injection room 
trial: Politics and controversies. 
Nordic Studies on Alcohol & 
Drugs, 25, 269–283. 
Norway In December 2004 a provisional legislative proposal was passed by the Norwegian Parliament for the establishment of a SIF, however politicians took  
unusual pains to detail the practicalities related to how the injecting room should be organized. Dilemmas faced included whether only injecting of heroin  
should be permitted, how to decide who to admit, and more generally how far society should go in providing help that may also prolong substance abuse.  
The evaluation of the trial was unable to determine with certainty whether the objectives of the trial were achieved, partly because the targets are methodologically and 
practically difficult to measure. An injecting room arrangement in the form set out under the Norwegian trial scheme presents staff with several difficulties to overcome. 
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Table 5: Qualitative studies (n=12 papers) 
Authors & Publication Year Outcomes 
Examined 
Study period & 
location 
Aim/Description Findings Unresolved Issues/ Notable 
Limitations 
Krüsi, A., Small, W., Wood, 
E., & Kerr, T. (2009). An 
integrated supervised 
injecting program within a 
care facility for HIV-positive 
individuals: a qualitative 
evaluation. AIDS Care, 21(5), 
638-644. 
* Access to 
prevention and care 
services for HIV-
positive IDUs 
May/Jun 2007 
 
Vancouver 
This qualitative study explored SIF 
staffs' and HIV-positive IDUs' 
perspectives on the effect of the SIF 
in relation to access to care services. 
Conducted a thematic analysis on 
recorded interviews 
Participants and staff viewed the SIF as facilitating access to 
care by building more open and trusting relationships with staff, 
facilitating engagement in safer injection education and 
improving the management of injection-related infections. 
Feelings of shame and fear of judgment in relation to their drug 
use were identified as a barrier in service uptake 
The study may not be representative, 
as there may have been over 
reporting of socially desirable views 
Small, W., Van Borek, N., 
Fairbairn, N., Wood, E., & 
Kerr, T. (2009). Access to 
health and social services for 
IDU: The impact of a 
medically supervised 
injection facility. Drug and 
Alcohol Review, 28(4), 341-
346. 
* Access to health 
and social services 
Nov 2005- Feb 
2006  
 
Vancouver 
This qualitative study explored IDUs' 
perspectives on the effect of the SIF 
in relation to access to health and 
social services. Conducted a thematic 
analysis on recorded interviews. 
There was also a small descriptive 
supplementary qualitative analysis 
Participants indicated that the SIF healthcare model is more 
accessible for IDU than conventional programs because of the 
nonjudgmental and integrated care, timely access to primary 
health care and referrals, and improved access to counselling 
and social services. The majority of participants indicated that 
the SIF facilitates access to care and services. The quantitative 
data showed that 44% of participants accessed medical care 
and 94% nonmedical services on-site. Lastly, 24% of participants 
reported that they would not have accessed the services they 
obtained at the SIF had Insite not been available 
Uses the same data as  Small, Wood, 
Lloyd-Smith, Tyndall & Kerr (2008), 
but addresses different questions. 
Unclear how much overlap there is in 
the results. Both studies use 
thematic analyses and the limitations 
of such a methodology should be 
taken into consideration when 
interpreting results 
Small, W., Wood, E., Lloyd-
Smith, E., Tyndall, M., & 
Kerr, T. (2008). Accessing 
care for injection-related 
infections through a 
medically supervised 
injecting facility: A 
qualitative study. Drug and 
Alcohol Dependence, 98(1-
2), 159-162. 
* Care for injection-
related infections at 
the SIF 
Nov 2005- Feb 
2006 
 
Vancouver 
This qualitative study explored IDUs' 
perspectives on the effect of the SIF 
in relation to healthcare access and 
management of injection-related 
infections. Conducted a thematic 
analysis on recorded interviews 
Participants indicated positive reports of assessment and care 
of injection-related infections on-site, and that the SIF connects 
IDU to off-site medical services by supplying referrals and 
transport. It was suggested that the presence of nursing 
personnel in the context of a SIF serves to address social and 
structural barriers that often impede IDU access to healthcare, 
such as prejudice encountered in conventional healthcare 
settings 
Uses the same data as  Small, Van 
Borek, Fairbairn, Wood & Kerr 
(2009), but the current study 
addresses infections specifically. 
Unclear how much overlap there is in 
the results 
Kerr, T., Small, W., Moore, 
D., & Wood, E. (2007). A 
micro-environmental 
intervention to reduce the 
harms associated with drug-
related overdose: Evidence 
from the evaluation of 
Vancouver's safer injection 
facility. International Journal 
of Drug Policy, 18(1), 37-45. 
* Overdose risk Nov 2005- Feb 
2006 
 
Vancouver 
This qualitative study explored IDUs' 
perspectives on the effect of the SIF 
in relation to overdose risk and 
management. Conducted a thematic 
analysis on recorded interviews 
Participants indicated that the SIF can address some of the risks 
associated with overdose, including rapid response by staff, 
being less rushed with injections, not being alone, and it also 
alleviates also fears about overdosing in public, such as getting 
robbed or arrested, and using substances of unknown 
purity/composition. They also identified some barriers to using 
the SIF, including the wait time and the restriction on level of 
intoxication (IDUs reported being roused by staff for being too 
intoxicated) 
Socially desirable responding may 
have influenced results 
DeBeck, K., Wood, E., Zhang, 
R., Tyndall, M., Montaner, J., 
& Kerr, T. (2008). Police and 
public health partnerships: 
Evidence from the 
evaluation of Vancouver's 
supervised injection facility. 
Substance Abuse Treatment, 
Prevention, and Policy, 
* Referral by local 
police to SIF 
Dec 2003- Nov 
2005 
 
Vancouver 
Cross-sectional study of IDUs 
recruited from the SIF and examines 
what proportion of these were 
referred by Police 
Approximately 17% of participants reported having been 
referred to the SIF by Vancouver police officers, and those 
engaged in sex work and frequent cocaine injection were more 
likely to be referred. They suggests that the SIF is providing 
Police with an avenue to promote public health. 
The measures relied on self-report 
18 
 
3(11), 5. 
Fast, D., Small, W., Wood, E., 
& Kerr, T. (2008). The 
perspectives of injection 
drug users regarding safer 
injecting education 
delivered through a 
supervised injecting facility. 
Harm Reduction Journal, 
5(32), 8. 
* Safer injecting 
education 
Nov 2005- Feb 
2006 
 
Vancouver 
This qualitative study explored IDUs' 
perspectives on the effect of the SIF 
in relation to safer injecting practices 
through education at the SIF. 
Conducted a thematic analysis on 
recorded interviews 
IDUs indicated significant gaps in knowledge regarding safer 
injecting practices, and that these knowledge deficits result in 
unsafe injecting practices and negative health outcomes. IDUs 
indicated that safer injecting education at the SIF allows clients 
to identify and address these gaps through educational 
messaging that occurs as a part of the drug use cycle and not 
outside of it, in situ demonstration of techniques during the 
process of injecting, and enhanced opportunities to seek help 
from healthcare professionals. IDUs indicated that the overall 
environment of the SIF promotes safer injecting practices both 
within and outside of the SIF 
Socially desirable responding may 
have influenced results 
Kimber, J., Hickman, M., 
Degenhardt, L., Coulson, T., 
& Van Beek, I. (2008). 
Estimating the size and 
dynamics of an injecting 
drug user population and 
implications for health 
service coverage: 
comparison of indirect 
prevalence estimation 
methods. Addiction, 
103(10), 1604-1613. 
* Use of SIF by IDU  Nov 2001- Oct 
2002 
 
Sydney 
Used a set of indirect prevalence 
estimation methods to estimate 
Sydney's SIF coverage of King's Cross 
IDU population and their injections 
Estimates of IDU coverage suggest that more than two-thirds of 
the resident IDU population had visited the SIF at least once, 
and it accounted for less than one in 10 injections occurring in 
Kings Cross. 
There are some caveats around the 
indirect prevalence estimation, and 
some methodological challenges 
remain. 
Fairbairn, N., Small, W., 
Shannon, K., Wood, E., & 
Kerr, T. (2008). Seeking 
refuge from violence in 
street-based drug scenes: 
Women’s experiences in 
North America’s first 
supervised injection facility. 
Social Science & Medicine, 
67, 817—823. 
*Reasons for using 
SIF, and impacts of 
SIF use on violence 
and associated risk 
November 2005-
March 2007 
 
Vancouver 
Semi-structured qualitative 
interviews conducted with 25 women 
recruited from the Scientific 
Evaluation of Supervised Injecting 
(SEOSI) cohort of SIF users in 
Vancouver. 
Examines the opinions of women on how the SIF mediates the 
impact of violence on women. The perspectives of women 
participating in this study suggest that the SIF is a unique 
controlled environment where women who inject drugs are 
provided refuge from violence and gendered norms that shape 
drug preparation and consumption practices. Further, by 
enabling increased control over drugs and the administration of 
drugs, the SIF promotes enhanced agency at the point of drug 
consumption. 
 
Small, W., Ainsworth, L., 
Wood, E., & Kerr, T. (2010). 
IDU perspectives on the 
design and operation of 
North America’s first 
medically supervised 
injection facility. Substance 
Use & Misuse, 46, 561—568. 
*Discussion of the 
design and 
operation of the 
SIF, as well as 
potential barriers to 
accessing the SIF 
November 2005 
to February 2006 
 
Vancouver 
In-depth qualitative interviews with 
50 IDUs aimed at discussing the 
design and operation of the SIF, as 
well as potential barriers to accessing 
the SIF. 
Although the environment and operation of the SIF are well 
accepted, long wait times and limited operating hours, as well 
as regulations that prohibit sharing drugs and assisted 
injections, pose barriers to using the SIF. Modifying operating 
procedures and expanding the capacity of the current facility 
could address these barriers 
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Solai, S., Dubois-Arber, F., 
Benninghoff, F. & Benaroyo, 
L. (2006). Ethical reflections 
emerging during the activity 
of a low threshold facility 
with supervised drug 
consumption room in 
Geneva, Switzerland. 
International Journal of Drug 
Policy, 17, 17–22. 
*Ethical conflicts at 
work 
2003 
 
Geneva 
This study, including a questionnaire, 
observations, and focus groups, 
aimed to identify situations where SIF 
staff were presented with ethical 
dilemmas or conflicts.  
Situations associated with ethical conflicts for staff were 
assisting clients to inject, client refusal to seek treatment in 
spite of poor health, new injectors, prohibition of access to 
minors, pregnant clients, client self mutilation, and non-
participation in proposed activities. The study showed that 
despite Quai 9’s clear objectives, expressed philosophy, and 
operational rules, the staff were frequently exposed to ethically 
conflicting situations. However, open and structured discussion 
of these situations using an ethical framework which allowed 
the identification of different norms and discussion of their 
respective importance in order to reach a common decision was 
feasible and useful in a DCR setting. 
 
Wegner, L. D., Arreola, S. G., 
& Kral, A. H. (2011). The 
prospect of implementing a 
safer injecting facility in San 
Francisco: perspectives of 
community stakeholders. 
International Journal of Drug 
Policy, 22, 239—241. 
*Stakeholder 
concerns 
June to October 
2009 
 
San Francisco 
Qualitative in-depth interviews were 
conducted with 20 purposively 
sampled stakeholders 
including representatives from 
neighbourhood and business 
associations, politicians, law 
enforcement, 
religious leaders, school officials, 
community activists and service 
providers.  
 
Stakeholders were concerned that implementation of a SIF 
would further degrade a community struggling with safety and 
cleanliness and questioned the efficacy of harm reduction 
strategies to address drug use. Stakeholders were open to 
dialogue about how a SIF might support neighbourhood 
goals, stressed the importance of respect and collaboration 
between stakeholders and those potentially implementing a 
SIF, and were interested in evidence of the impact SIFs have on 
communities. Government protection and political leadership 
would be necessary to implement a SIF.  
Data are derived from 
a small sample of interviews, and  
participants were recruited 
through snowball sampling methods 
and were not a representative 
sample. In addition, the interviews 
were conducted during a time of 
economic crisis and political 
uncertainty in San Francisco, and 
may not reflect concerns in more 
stable times. 
Fairbairn, N., Small, W., Van 
Borek, N., Wood, E., & Kerr, 
T. (2010). Social structural 
factors that shape assisted 
injecting practices among 
injection drug users in 
Vancouver, Canada: A 
qualitative study. Harm 
Reduction Journal, 7, 1—7. 
*Injecting practices June to July 2007 
 
Vancouver 
Examines a group of people who 
report needing help injecting. The 
study investigated the social 
structural factors that shape risks 
related to assisted injection, and the 
harms that may result.  
Twenty semi-structured qualitative interviews were conducted 
with IDU enrolled in the ACCESS or Vancouver Injection Drug 
Users Study (VIDUS). Barriers to self-injecting included a lack of 
knowledge of proper injecting technique, a loss of accessible 
veins, and drug withdrawal. The exchange of money or drugs 
for assistance with injecting was common. Harms experienced 
by IDU requiring assistance injecting included theft of the drug, 
missed injections, overdose, and risk of blood-borne disease 
transmission. Increased vulnerability to HIV/HCV infection 
within the context of intimate relationships was represented in 
participant narratives. IDU identified a lack of services available 
for those who require assistance injecting, with notable 
mention of restricted use of Vancouver's supervised injection 
facility. 
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Table 6: Descriptive studies, other papers (n=63 papers) 
Reference Description 
Anoro, M., Ilundain, E., & Santisteban, O. (2003). Barcelona's safer injection facility-EVA: A harm reduction program lacking official support. 
Journal of Drug Issues, 33, 689-711. 
Documents the history of Barcelona’s SIF, operation, service use, client 
characteristics, advantages and disadvantages and future proposals 
Benninghoff, F., Solai, S., Huissoud, T., & Dubois-Arber, F. (2003). Evaluation de Quai 9 “espace d’accueil et d’injection” à Genève: période 
12/2001–12/2000. Lausanne: Institut universitaire de médecine sociale et préventive. 
Provides descriptive data on the SIF in Geneva, including some data on 
public syringes collected, hospitalisations, HIV infections, overdoses, and 
police activity 
Beyrer, C. (2011). Safe injection facilities save lives. Lancet, 377, 1385—1386. Comment preceding a study in journal; restates results 
Broadhead, R. S. (2003). Safer injection facilities: Obstacles, proposals, policies, and program evaluations. Journal of Drug Issues, 33, 533–537. Editorial introducing a SIF edition of the journal 
Broadhead, R. S., Borch, C. A., Farrell, J., Villemez, W. J., & Altice, F. (2003). Safer injection sites in New York City: A utilization survey of injection 
drug users. Journal of Drug Issues, 33, 733—750. 
Examines IDUs’ perspectives on establishing a SIF in New York 
De Jong, W., & Weber, U. (1999). The professional acceptance of drug use: A closer look at drug consumption rooms in the Netherlands, 
Germany and Switzerland. International Journal of Drug Policy, 10, 99—108. 
Provides a historical overview of SIFs and inhalation rooms in Europe, 
including examining factors that seem to lead to their success 
Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., McDonald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment 
of supervised injecting centres in Australia. Drug & Alcohol Review, 19, 337-346. 
Historical review of the development and impact of SIFs worldwide, 
including non-English papers. Also provides a review of the Australian 
context and developments 
Dooling, K., & Rachlis, M. (2010). Vancouver’s supervised injection facility challenges Canada’s drug laws. Canadian Medical Association Journal, 
182, 1440—1444. 
Reviews the historical process that led to the Vancouver SIF’s establishment, 
and provides an update on recent legal developments 
Dubois-Arber, F., Benninghoff, F., & Jeannin, A. (2008). Typology of injection profiles of clients of a supervised drug consumption facility in 
Geneva, Switzerland. European Addiction Research, 14, 1–10.  
Establishes a typology of different types of SIF clients in Geneva, using 
cluster analysis 
Expert Advisory Committee (2008). Vancouver's INSITE service and other supervised injection sites: What has been learned from research? Final 
report of the Expert Advisory Committee [Government report]. Retrieved from http://www.hc-sc.gc.ca/ahc-asc/pubs/_sites-
lieux/insite/index-eng.php#app_a  
Provides data on service utilisation, client characteristics, and a range of 
outcomes, restated from other studies on the Vancouver SIF 
Fischer, B., Rehm, J., Kim, G., & Robins, A. (2002). Safer Injecting Facilities (SIFs) for Injection Drug Users (IDUs) in Canada: A review and call for 
an evidence-focused pilot trial. Canadian Journal of Public Health, 93, 336–338. 
Short commentary published before the opening of the Vancouver SIF, 
supporting the SIF but highlighting some obstacles to be overcome 
Fortson, R. (2006). Setting up a drug consumption room: Legal issues. York: Joseph Rowntree Foundation. Supporting evidence for the Independent Working Group (2006) 
Fry, C., Fox, S., & Rumbold, G. (1999). Establishing safe injecting rooms in Australia: Attitudes of injecting drug users. Australian & New Zealand 
Journal of Public Health, 23, 501-504. 
Surveys IDUs in Melbourne 
Fry, C. L. (2003). Safer injecting facilities in Vancouver: Considering issues beyond potential use. Canadian Medical Association Journal, 169, 
777–778. 
Comments on Kerr, Wood, Small, Palepu & Tyndall (2003), in considering 
issues around house rules of SIFs 
Fry, C. L., Cvetkovski, S., & Cameron, J. (2006). The place of supervised injecting facilities within harm reduction: Evidence, ethics, and policy. 
Addiction, 101, 465–467. 
Short commentary considering the ethical and value dimensions of SIFs. Also 
see Fischer, Turnbull, Poland & Haydon (2004) and Hathaway & Tousaw 
(2008) 
Hagan, H. (2002). Supervised injection rooms—prospects and limitations. International Journal of Drug Policy, 13, 449–451. Short commentary considering issues around house rules of SIFs. Also see 
Fry (2003) and Kerr, Wood, Small, Palepu & Tyndall (2003) 
Hall, W., & Kimber, J. (2005). Being realistic about benefits of supervised injecting facilities. Lancet, 366, 271–272. Short commentary discussing limitations of SIF research and expectations 
Hunt, N. (2006a). Indicators of the need for consumption rooms in the UK. York: Joseph Rowntree Foundation. Supporting evidence for the Independent Working Group (2006) 
Green, T., Hankins, C., Palmer, D., Boivin, J. F., & Platt, R. (2003). Ascertaining the need for a Supervised Injecting Facility (SIF): The burden of 
public injecting in Montreal, Canada. Journal of Drug Issues, 33, 713—731. 
Provides descriptive data on the patterns of drug use consumption and risk-
related characteristics of IDU in Montreal 
Kemmesies, U. E. (1999). The open drug scene and the safe injection room offers in Frankfurt am Main 1995. Münster: Indro. Retrieved from 
http://www.indro-online.de/injection_room.htm. 
Examines drug users in Frankfurt, assessing drug use patterns, 
demographics, SIF service use and suggestions for service changes 
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Kerr, T., Tyndall, M. W., Lai, C., Montaner, J. S. G., & Wood, E. (2006). Drug-related overdoses within a medically supervised safer injection 
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Glossary 
 
SIF= Supervised Injecting Facility 
IDU= Injecting Drug User 
AHR= Adjusted Hazard Ratio 
AOD= Adjusted Odds Ratio 
95% CI= Ninety-five percent confidence intervals 
 
The Scientific Evaluation of Supervised Injecting (SEOSI) study is a prospective cohort of IDUs randomly 
recruited from Insite, Vancouver’s SIF 
 
The Vancouver injecting drug users study (VIDUS) is a cohort of NON randomly recruited IDUs in Vancouver, 
some of whom access Insite 
 
Notes 
 
Search Terms used: 
• Supervised inject* 
• Inject* and (opiate, opioid, heroin) 
• Consumption and (facility, site, centre, room) 
• (Site, facility, centre, supervis*) and inject* 
• Shooting or gallery 
• (Harm NEXT reduction) and (opiate, opioid, heroin, inject*) 
 
Databases included:  
• MEDLINE 
• Google Scholar (using backwards-citation sourcing) 
• UNSW Library catalogue 
• Targeted organisations, e.g., European Monitoring Centre for Drugs and Drug Addiction, Australian 
Drug Law Reform Foundation, Drug Policy Alliance, Harm Reduction Coalition, Transnational Institute, 
Transform Drug Policy Foundation, International Centre for Science in Drug Policy 
• Following up on studies cited in grey literature/reviews 
